TY - JOUR
T1 - Effects of atrial natriuretic factor on human platelet function
AU - De Caterina, Raffaele
AU - Volpe, Massimo
AU - Atlas, Steven A.
AU - Weksler, Babette B.
N1 - Funding Information:
These studies were supported by Thrombosis SCOR grant HL 18828 from the National Institutes of Health (Dr. Weksler) and Hypertension SCOR grant HL 18323 (Dr. Atlas). Dr. De Caterina, on leave of absence from the Institute of Clinical Physiology, C.N.R., Pisa, Italy, held a Fogarty International Research Fellowship from the U.S. Public Health Sevice. Dr. Volpe held a fellowship from the C.N.R., Italy, sponsored by N.A.T.O.
PY - 1985/10/14
Y1 - 1985/10/14
N2 - We examined the hypothesis that atrial natriuretic factor (ANF), a substance with known vasorelaxant activities, shares with other vasodilators the property of inhibiting platelet function. Aggregation of citrated platelet-rich plasma (PRP) from 23 healthy volunteers induced by ADP, adrenaline, arachidonic acid, collagen, γ-thrombin, the endoperoxide analogue U-44069, serotonin, the calcium ionophore A-23187 or platelet aggregating factor was measured after incubation of PRP with ANF for 3 minutes at concentrations of 4 × 10-9, 4 × 10-8 and 4 × 10-7M or vehicle as control. ANF decreased ADP-induced aggregation significantly (P<0.02), but only at the highest concentration used and to a minor extent (control: 73.6±11.2%; after ANF 4 × 10-7M: 60.0±17.1%, mean±S.D., n=39) by a selective inhibitory effect on the secondary wave; neither aggregation by all other agents tested nor thromboxane B2 generation induced by ADP and adrenaline was altered by incubation with ANF. Although ANF thus has detectable effects on ADP-induced platelet aggregation in vitro, these data suggest that ANF is unlikely to be a physiologically significant modulator of platelet function.
AB - We examined the hypothesis that atrial natriuretic factor (ANF), a substance with known vasorelaxant activities, shares with other vasodilators the property of inhibiting platelet function. Aggregation of citrated platelet-rich plasma (PRP) from 23 healthy volunteers induced by ADP, adrenaline, arachidonic acid, collagen, γ-thrombin, the endoperoxide analogue U-44069, serotonin, the calcium ionophore A-23187 or platelet aggregating factor was measured after incubation of PRP with ANF for 3 minutes at concentrations of 4 × 10-9, 4 × 10-8 and 4 × 10-7M or vehicle as control. ANF decreased ADP-induced aggregation significantly (P<0.02), but only at the highest concentration used and to a minor extent (control: 73.6±11.2%; after ANF 4 × 10-7M: 60.0±17.1%, mean±S.D., n=39) by a selective inhibitory effect on the secondary wave; neither aggregation by all other agents tested nor thromboxane B2 generation induced by ADP and adrenaline was altered by incubation with ANF. Although ANF thus has detectable effects on ADP-induced platelet aggregation in vitro, these data suggest that ANF is unlikely to be a physiologically significant modulator of platelet function.
UR - http://www.scopus.com/inward/record.url?scp=0021840463&partnerID=8YFLogxK
U2 - 10.1016/0024-3205(85)90078-5
DO - 10.1016/0024-3205(85)90078-5
M3 - Article
C2 - 2931566
AN - SCOPUS:0021840463
SN - 0024-3205
VL - 37
SP - 1395
EP - 1402
JO - Life Sciences
JF - Life Sciences
IS - 15
ER -